Mental health and non-drug digital treatments provider Big Health has acquired digital therapeutic developer Limbix for an undisclosed sum.
Established in 2016, Limbix is claimed to have developed the first evidence-based digital therapeutic for teens and young adults with depression symptoms.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Through its Series A funding round, the company raised $30m and developed a research-based pipeline of adolescent products.
Limbix has developed a digital therapeutic called SparkRx to provide a neurobehavioral intervention (cognitive behavioural therapy (CBT) – behavioural activation) for patients aged between 13 and 22 years as an adjunct treatment for depression symptoms.
Supported by trial data showing a clinically meaningful reduction in depression symptoms, the self-guided CBT-based treatment is intended to teach skills such as mindfulness, problem-solving, behavioural activation and mood tracking.
The US Food and Drug Administration has not granted clearance or approval for SparkRx.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataBig Health CEO and executive chairman Arun Gupta said: “We must continue to rise to the challenge of the mental health crisis – our acquisition of Limbix is a strategic milestone in advancing our mission to help millions back to good mental health.
“Our portfolio of evidence-based, clinically validated digital treatments will enable a record number of adult and adolescent patients to get immediate access to safe and effective non-drug options.”
Big Health provides a number of mental health treatments and therapies, including the Sleepio and Daylight programmes for insomnia and anxiety treatments, respectively.
